These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1374546)

  • 1. Effect of clinical status and treatment on the frequency of CD5+ B cells in patients with myasthenia gravis.
    Ragheb S; Lisak RP
    Neurology; 1992 May; 42(5):1076-80. PubMed ID: 1374546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of CD5+ B lymphocytes do not differ between patients with myasthenia gravis and healthy individuals.
    Yi Q; Ahlberg R; Pirskanen R; Lefvert AK
    Neurology; 1992 May; 42(5):1081-4. PubMed ID: 1374547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency of CD5+ B lymphocytes in the peripheral blood of patients with myasthenia gravis.
    Ragheb S; Lisak RP
    Neurology; 1990 Jul; 40(7):1120-4. PubMed ID: 1694020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD5+ B cells and myasthenia gravis.
    Araga S; Kishimoto M; Adachi A; Nakayasu H; Takenaka T; Takahashi K
    Autoimmunity; 1995; 20(2):129-34. PubMed ID: 7578869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.
    Heidenreich F; Jovin T
    J Neurol; 1996 Jan; 243(1):57-62. PubMed ID: 8869388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental autoimmune myasthenia gravis and CD5+ B-lymphocyte expression.
    Lee KW; Lee SH; Kim HJ; Kim JM; Choi YM; Motomura M
    J Korean Med Sci; 1999 Feb; 14(1):75-9. PubMed ID: 10102528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD5+ B cells in myasthenia gravis. Clinical correlations.
    Ragheb S; Lisak RP
    Ann N Y Acad Sci; 1992 May; 651():586-7. PubMed ID: 1376084
    [No Abstract]   [Full Text] [Related]  

  • 8. B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis.
    Yilmaz V; Oflazer P; Aysal F; Parman YG; Direskeneli H; Deymeer F; Saruhan-Direskeneli G
    Autoimmunity; 2015 Jun; 48(4):201-7. PubMed ID: 25518708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-1 cells in systemic autoimmune responses: IgM+, Fc epsilon Rdull B cells are lost during chronic graft-versus-host disease but not in murine AIDS or collagen-induced arthritis.
    Iciek LA; Waldschmidt TJ; Griffiths MM; Brooks KH
    Immunol Invest; 1994 Aug; 23(4-5):293-311. PubMed ID: 7525472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD5+ B-cells at the onset of type I diabetes and in the prediabetic period.
    Smerdon RA; Peakman M; Hussain MJ; Wong FS; Watkins PJ; Leslie RD; Vergani D
    Diabetes Care; 1994 Jul; 17(7):657-64. PubMed ID: 7523048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in peripheral blood CD5 (Bla) B-cell populations and autoantibodies following blood transfusion.
    Paglieroni TG; Ward J; Holland PV
    Transfusion; 1995 Mar; 35(3):189-98. PubMed ID: 7533341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in lymphocyte subsets in myasthenia gravis: correlation with level of antibodies to acetylcholine receptor and age of patient.
    Schlesinger I; Rabinowitz R; Brenner T; Abramsky O; Schlesinger M
    Neurology; 1992 Nov; 42(11):2153-7. PubMed ID: 1436527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased CD5-positive B lymphocytes in type I diabetes.
    Muñoz A; Gallart T; Viñas O; Gomis R
    Clin Exp Immunol; 1991 Feb; 83(2):304-8. PubMed ID: 1704297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD5+ B cells and naturally occurring autoantibodies in cancer patients.
    Stein R; Witz IP; Ovadia J; Goldenberg DM; Yron I
    Clin Exp Immunol; 1991 Sep; 85(3):418-23. PubMed ID: 1716541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.
    Vrolix K; Fraussen J; Losen M; Stevens J; Lazaridis K; Molenaar PC; Somers V; Bracho MA; Le Panse R; Stinissen P; Berrih-Aknin S; Maessen JG; Van Garsse L; Buurman WA; Tzartos SJ; De Baets MH; Martinez-Martinez P
    J Autoimmun; 2014 Aug; 52():101-12. PubMed ID: 24439114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection.
    Zuckerman E; Kessel A; Slobodin G; Sabo E; Yeshurun D; Toubi E
    J Virol; 2003 Oct; 77(19):10432-6. PubMed ID: 12970428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis.
    Motobayashi M; Inaba Y; Nishimura T; Kobayashi N; Nakazawa Y; Koike K
    Pediatr Neurol; 2015 Apr; 52(4):404-9. PubMed ID: 25661289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis: from autoantibodies to therapy.
    Mantegazza R; Bernasconi P; Cavalcante P
    Curr Opin Neurol; 2018 Oct; 31(5):517-525. PubMed ID: 30156572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic and functional abnormalities of B cells in myasthenia gravis.
    Ragheb S; Lisak RP
    Ann N Y Acad Sci; 1993 Jun; 681():256-63. PubMed ID: 7689307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.